DiaMedica Therapeutics Inc (DMAC)
3.00
+0.37
(+14.07%)
USD |
NASDAQ |
May 03, 16:00
3.005
0.00 (0.00%)
After-Hours: 20:00
DiaMedica Therapeutics Research and Development Expense (Quarterly): 3.677M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 3.677M |
| September 30, 2023 | 3.272M |
| June 30, 2023 | 2.543M |
| March 31, 2023 | 3.618M |
| December 31, 2022 | 2.27M |
| September 30, 2022 | 1.64M |
| June 30, 2022 | 1.955M |
| March 31, 2022 | 1.974M |
| December 31, 2021 | 1.871M |
| September 30, 2021 | 2.332M |
| June 30, 2021 | 2.156M |
| March 31, 2021 | 2.406M |
| December 31, 2020 | 3.097M |
| September 30, 2020 | 2.158M |
| June 30, 2020 | 1.60M |
| March 31, 2020 | 1.349M |
| December 31, 2019 | 1.802M |
| September 30, 2019 | 1.617M |
| June 30, 2019 | 1.874M |
| March 31, 2019 | 2.607M |
| December 31, 2018 | 1.451M |
| September 30, 2018 | 1.21M |
| June 30, 2018 | 1.07M |
| March 31, 2018 | 0.791M |
| December 31, 2017 | 0.6462M |
| Date | Value |
|---|---|
| September 30, 2017 | 0.4901M |
| June 30, 2017 | 0.9127M |
| March 31, 2017 | 1.157M |
| December 31, 2016 | 0.4085M |
| September 30, 2016 | 0.7354M |
| June 30, 2016 | 0.3579M |
| March 31, 2016 | 0.2262M |
| December 31, 2015 | 0.3567M |
| September 30, 2015 | 0.1465M |
| June 30, 2015 | 0.2031M |
| March 31, 2015 | 0.305M |
| December 31, 2014 | 0.421M |
| September 30, 2014 | 0.73M |
| June 30, 2014 | 0.9446M |
| March 31, 2014 | 1.675M |
| December 31, 2013 | 1.030M |
| September 30, 2013 | 1.167M |
| June 30, 2013 | 1.892M |
| March 31, 2013 | 2.418M |
| December 31, 2012 | 2.861M |
| September 30, 2012 | 2.289M |
| June 30, 2012 | 2.013M |
| March 31, 2012 | 1.668M |
| December 31, 2011 | 1.738M |
| September 30, 2011 | 1.366M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.349M
Minimum
Mar 2020
3.677M
Maximum
Dec 2023
2.274M
Average
2.156M
Median
Jun 2021
Research and Development Expense (Quarterly) Benchmarks
| NextCure Inc | 11.83M |
| NovaBay Pharmaceuticals Inc | 0.004M |
| Palatin Technologies Inc | 5.554M |
| iBio Inc | 1.535M |
| Theriva Biologics Inc | 4.196M |